Overview
NEPTUNUS (000078)
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company als...
- Open
- 1.30
- High
- 1.32
- Low
- 1.26
- Prev. Close
- 1.28
- Volume
- 333.91K
- Turnover
- 42.88M
- Avg Price
- 1.28
- Bid/Ask Ratio
- --
- Amplitude
- 4.69%
- 52wk High
- 5.70
- Volume Ratio
- 0.00
- Turnover Ratio
- 1.27%
- 52wk Low
- 1.19
- Float Mkt Cap
- 3.34B
- Market CapCNY
- 3.34B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.365
- EPSDynamic
- -0.188
- EPSStatic
- --
- BVPS
- 0.33
- P/B
- 3.90
- Circulating Supply
- 2.63B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 2.63B
- Min lot size
- 100
- Currency
- CNY
News
Wallstreetcn · Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%
Wallstreetcn · Pharmaceutical commercial stocks are repeatedly active, NEPTUNUS has a 6-day consecutive limit-up, Realcan hits the limit-up, HRPC, SHKK, INT'L GROUP, and others follow suit. In news, China's drug price registration system has officially launched
Zhitong · NEPTUNUS: HW130 injection completed Phase I clinical trial
Zhitong · NEPTUNUS terminates the matter of change in control
Zhitong · The pharmaceutical commercial sector has seen a short-term surge, with YIXINTANG hitting the limit up
